Al-Swailem Samar A, Al-Rajhi Ali A, Wagoner Michael D
Anterior Segment Division, Department of Ophthalmology, King Khaled Eye Specialist Hospital, Riyadh, Kingdom of Saudi Arabia.
Ophthalmology. 2005 Feb;112(2):220-4. doi: 10.1016/j.ophtha.2004.08.017.
To determine the prognosis of penetrating keratoplasty (PK) for macular corneal dystrophy (MCD).
Single-center, retrospective, interventional, noncomparative case series.
One hundred forty-one patients (229 eyes) with MCD.
Retrospective review of the medical record of every patient who underwent primary PK for histopathologically confirmed MCD at the King Khaled Eye Specialist Hospital between January 1, 1983 and December 31, 2002 and for whom at least 12 months of follow-up is available.
Visual acuity (VA), graft survival, and postoperative complications.
After a mean follow-up period of 5.9+/-3.8 years (range, 1-17), the mean best-corrected VA was 20/50. At the most recent visit, 206 (90.0%) grafts were clear, and 23 (10.0%) had failed. Probabilities of graft survival were 98.1% at 1 year, 89.8% at 5 years, 82.1% at 10 years, and 74.1% at 15 years. There was a statistically significant increased likelihood of graft failure if the patient was older than 40 years at the time of surgery (P<0.00003). The differences in graft failure between patients older than 40 and those younger were not attributable to statistically significant differences in duration of follow-up, donor age, or donor endothelial cell counts. Corneal endothelial rejection episodes occurred in 47 (20.0%) grafts, but resulted in irreversible graft failure in only 8 (3.5%) eyes. Eighteen (27.3%) of 66 eyes with a recipient size of > or =7.5 mm developed a graft rejection episode, compared with 27 (16.6%) of 163 eyes with a recipient size of <7.5 mm (P = 0.04). Microbial keratitis occurred in 14 (6.1%) grafts and was more likely to occur in patients over 40 (14.0% vs. 3.0%, P = 0.01). Clinically significant recurrence was observed in 12 (5.2%) grafts, after a mean interval of 84+/-48.2 months, and was directly related to patient age (P = 0.04) and inversely related to donor graft size (P = 0.04).
Good visual results and excellent graft survival can be achieved after PK for MCD. The risk of graft failure is higher in patients older than 40 years.
确定穿透性角膜移植术(PK)治疗黄斑角膜营养不良(MCD)的预后。
单中心、回顾性、干预性、非对照病例系列。
141例(229只眼)MCD患者。
回顾性分析1983年1月1日至2002年12月31日在沙特国王哈立德眼科专科医院接受原发性PK治疗且组织病理学确诊为MCD、至少有12个月随访资料的每例患者的病历。
视力(VA)、植片存活情况及术后并发症。
平均随访5.9±3.8年(范围1 - 17年),平均最佳矫正视力为20/50。在最近一次随访时,206只(90.0%)植片透明,23只(10.0%)植片失败。植片1年、5年、10年和15年的存活概率分别为98.1%、89.8%、82.1%和74.1%。手术时年龄大于40岁的患者植片失败的可能性有统计学意义的增加(P<0.00003)。年龄大于40岁和小于40岁患者之间植片失败的差异并非归因于随访时间、供体年龄或供体内皮细胞计数的统计学显著差异。47只(20.0%)植片发生角膜内皮排斥反应,但仅8只(3.5%)眼导致不可逆的植片失败。66只受体植床尺寸≥7.5 mm的眼中有18只(27.3%)发生植片排斥反应;而163只受体植床尺寸 <7.5 mm的眼中有27只(16.6%)发生植片排斥反应(P = 0.04)。14只(6.1%)植片发生细菌性角膜炎,且更易发生于年龄大于40岁的患者(14.0% 对3.0%,P = 0.01)。12只(5.2%)植片观察到具有临床意义的复发,平均间隔时间为84±48.2个月,且与患者年龄直接相关(P = 0.04),与供体植片大小呈负相关(P = 0.04)。
MCD患者PK术后可获得良好的视力结果和优异的植片存活率。年龄大于40岁的患者植片失败风险更高。